logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

First-line therapies for metastatic NSCLC win FDA approval

FDA approves ramucirumab plus erlotinib and nivolumab plus ipilimumab and chemotherapy for mNSCLC.